PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.

Abstract Methotrexate (MTX) is commonly used to treat individuals with rheumatological and dermatologic disorders. Current American College of Rheumatology (ACR) and American Association of Dermatology (AAD) guidelines identify diabetes and obesity as risk factors for MTX-induced liver injury. Both diabetes and obesity are components of the metabolic syndrome, and are also risk factors for nonalcoholic fatty liver disease (NAFLD). NAFLD affects approximately 40% of the U.S. population, and those with more advanced NAFLD (i.e., nonalcoholic steatohepatitis with or without fibrosis) are likely to develop progressive liver disease. As such, individuals who are treated with MTX may need to be screened for advanced NAFLD, as this may put them at an increased risk of MTX-induced liver injury. In this mini-review, we review the current ACR and AAD guidelines on MTX hepatotoxicity, discuss the evidence (or lack thereof) of the impact of metabolic risk factors on MTX-induced liver injury and highlight the areas that need further research.
PMID
Related Publications

Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.

A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia.

The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease.

Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.

End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.

Authors

Mayor MeshTerms
Keywords

Chronic liver disease

Drug

Hepatotoxicity

Metabolic

Nonalcoholic steatohepatitis

Journal Title the american journal of the medical sciences
Publication Year Start




PMID- 28864376
OWN - NLM
STAT- MEDLINE
DA  - 20170902
DCOM- 20170908
LR  - 20170908
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 354
IP  - 2
DP  - 2017 Aug
TI  - Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.
PG  - 172-181
LID - S0002-9629(17)30139-8 [pii]
LID - 10.1016/j.amjms.2017.03.014 [doi]
AB  - Methotrexate (MTX) is commonly used to treat individuals with rheumatological and
      dermatologic disorders. Current American College of Rheumatology (ACR) and
      American Association of Dermatology (AAD) guidelines identify diabetes and
      obesity as risk factors for MTX-induced liver injury. Both diabetes and obesity
      are components of the metabolic syndrome, and are also risk factors for
      nonalcoholic fatty liver disease (NAFLD). NAFLD affects approximately 40% of the 
      U.S. population, and those with more advanced NAFLD (i.e., nonalcoholic
      steatohepatitis with or without fibrosis) are likely to develop progressive liver
      disease. As such, individuals who are treated with MTX may need to be screened
      for advanced NAFLD, as this may put them at an increased risk of MTX-induced
      liver injury. In this mini-review, we review the current ACR and AAD guidelines
      on MTX hepatotoxicity, discuss the evidence (or lack thereof) of the impact of
      metabolic risk factors on MTX-induced liver injury and highlight the areas that
      need further research.
CI  - Published by Elsevier Inc.
FAU - Shetty, Akshay
AU  - Shetty A
AD  - Division of Gastroenterology and Hepatology, Medical University of South
      Carolina, Charleston, South Carolina.
FAU - Cho, WonKyung
AU  - Cho W
AD  - Division of Gastroenterology and Hepatology, Medical University of South
      Carolina, Charleston, South Carolina.
FAU - Alazawi, William
AU  - Alazawi W
AD  - Department of Hepatology, Barts Health NHS Trust, London, United Kingdom; Centre 
      for Immunobiology, Blizzard Institute, Queen Mary University of London, London,
      United Kingdom.
FAU - Syn, Wing-Kin
AU  - Syn WK
AD  - Division of Gastroenterology and Hepatology, Medical University of South
      Carolina, Charleston, South Carolina; Section of Gastroenterology, Ralph H.
      Johnson Veterans Affairs Medical Center, Charleston, South Carolina. Electronic
      address: [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170314
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Dermatologic Agents)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - AIM
SB  - IM
MH  - Antirheumatic Agents/*adverse effects
MH  - Chemical and Drug Induced Liver Injury/*etiology
MH  - Dermatologic Agents/*adverse effects
MH  - Diabetes Mellitus/physiopathology
MH  - Humans
MH  - Metabolic Syndrome X/*physiopathology
MH  - Methotrexate/*adverse effects
MH  - Non-alcoholic Fatty Liver Disease/*chemically induced
MH  - Obesity/complications
MH  - Risk Factors
OTO - NOTNLM
OT  - Chronic liver disease
OT  - Drug
OT  - Hepatotoxicity
OT  - Metabolic
OT  - Nonalcoholic steatohepatitis
EDAT- 2017/09/03 06:00
MHDA- 2017/09/09 06:00
CRDT- 2017/09/03 06:00
PHST- 2016/11/16 [received]
PHST- 2017/02/10 [revised]
PHST- 2017/03/08 [accepted]
AID - S0002-9629(17)30139-8 [pii]
AID - 10.1016/j.amjms.2017.03.014 [doi]
PST - ppublish
SO  - Am J Med Sci. 2017 Aug;354(2):172-181. doi: 10.1016/j.amjms.2017.03.014. Epub
      2017 Mar 14.